Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration to manufacture and market Abacavir tablets.
The tablets, which are ready for launch, are the generic equivalent of ViiV Healthcare Company’s Ziagen tablets.
The drug is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
The annual sale of the product is approximately $88 million, the Hyderabad-based company said in a release on Tuesday.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.